CD44v4 Is a Major E-Selectin Ligand that Mediates Breast Cancer Cell Transendothelial Migration

Ke Zen, Dan-Qing Liu, Ya-Lan Guo et al. · 2008

Read CD44v4 Is a Major E-Selectin Ligand that Mediates Breast Cancer Cell Transendothelial Migration by Ke Zen, Dan-Qing Liu, Ya-Lan Guo et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001826.txt.

Introduction

Ke Zen and co-authors identified a molecule that helps breast cancer cells cross vessel walls in a 2008 PLOS ONE research article. Endothelial E-selectin plays a pivotal role in interactions between breast cancer cells and endothelial monolayers during metastasis. The counterreceptor on the cancer cell, and its role in transendothelial migration, were unknown.

The team reports that CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration. The full text gives the binding and migration assays. Metastasis requires cancer cells to exit the bloodstream; blocking the molecular handle they use could slow that step.

Catalog record

CREATORKe Zen, Dan-Qing Liu, Ya-Lan Guo et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001826

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

CD44v4 Is a Major E-Selectin Ligand that Mediates Breast Cancer Cell Transendothelial Migration Authors: Ke Zen, Dan-Qing Liu, Ya-Lan Guo, Chen Wang, Jun Shan, Ming Fang, Chen-Yu Zhang, Yuan Liu Published: 2008, PLOS ONE DOI: 10.1371/journal.pone.0001826 ABSTRACT Endothelial E-selectin has been shown to play a pivotal role in mediating cell–cell interactions between breast cancer cells and endothelial monolayers during tumor cell metastasis. However, the counterreceptor for E-selectin and its role in mediating breast cancer cell transendothelial migration remain unknown. By assessing migration of various breast cancer cells across TNF-α pre-activated human umbilical vein endothelial cells (HUVECs), we found that breast cancer cells migrated across HUVEC monolayers differentially and that transmigration was E-selectin dependent. Cell surface labeling with the E-selectin extracellular domain/Fc chimera (exE-selectin/Fc) showed that the transmigration capacity of breast cancer cells was correlated to both the expression level and localization pattern of E-selectin binding protein(s) on the tumor cell surface. The exE-selectin/Fc strongly bound to metastatic MDA-MB-231, MDA-MB-435 and MDA-MB-468 cells, but not non-metastatic MCF-7 and T47D cells. Binding of exE-selectin/Fc was abolished by removal of tumor cell surface sialyl lewis x (sLe x ) moieties. Employing an exE-selectin/Fc affinity column, we further purified the counterreceptor of E-selectin from metastatic breast cancer cells. The N-terminal protein sequence and cDNA sequence identified this E-selectin ligand as a ∼170 kD human CD44 variant 4 (CD44v4). Purified CD44v4 showed a high affinity for E-selectin via sLe x moieties and, as expected, MDA-MB-231 cell adhesion to and migration across HUVEC monolayers were significantly reduced by down-regulation of tumor cell CD44v4 via CD44v4-specific siRNA. We demonstrated, for the first time, that breast cancer cell CD44v4 is a major E-selectin ligand in facilitating tumor cell migration across endothelial monolayers. This finding offers new insights into the molecular basis of E-selectin–dependent adhesive interactions that mediate breast cancer cell transendothelial metastasis. INTRODUCTION Metastatic invasion is the primary cause of breast cancer mortality. A key step in the metastasis process is migration of tumor cells across the blood vessel-lining endothelial monolayers. It has been widely reported that endothelial cell E-selectin plays a pivotal role in mediating cell–cell interactions between tumor cells and endothelial monolayers during tumor metastasis [1] , [2] , [3] . The major ligand of endothelial E-selectin on the tumor cell surface has been identified as a sialylated glycan determinant, such as sialyl Lewis x moieties (sLe x ), which decorate the terminal extensions of O-linked or N-linked carbohydrates [4] . Interaction of tumor cell surface sLe x moieties and sLe x -decorated glycoproteins with endothelium E-selectin is a major component of cancer invasion and metastasis. A positive correlation between expression of E-selectin ligands such as sLe x moieties in tumor cells and tumor cell metastasis or invasion has been widely reported [5] , [6] . In breast cancer cells, several studies have also demonstrated a critical role for E-selectin in regulating tumor cell transendothelial migration [7] , [8] . However, the identity of the E-selectin ligand in breast cancer cells and its physiological contribution in regulating tumor cell transendothelial migration is unknown. Several leukocyte adhesion molecules, including leukocyte P-selectin glycoprotein ligand-1 (PSGL-1) and E-selectin ligand-1 (ESL-1), have been identified as ligands for endothelial E-selectin [9] . These interactions between PSGL-1, ESL-1 and E-selectin play a significant role in regulating leukocyte rolling process. Dimitroff et al. [10] reported that both E-selectin binding forms of PSGL-1 and ESL-1 are expressed on the human bone-metastatic prostate tumor MDA PCa 2b cell line, suggesting that these molecules may serve as E-selectin ligands in mediating tumor cell adhesion to or migration across endothelium. However, it is unclear whether breast cancer cells or other non-bone derived metastatic tumor cells express PSGL-1 or ESL-1. Recently, studies have demonstrated that CD44 variant isoforms (CD44v) in LS174T colon carcinoma cells possess selectin binding activity [11] , [12] , suggesting a broader role for CD44v in regulating tumor cell metastasis, particularly the event of migration across the vascular endothelium. CD44 was originally identified as a leukocyte homing receptor, and its globular amino-terminal domain contains hyaluronic acid (HA)–binding motifs and several potential glycosylation sites [13] . Through its interaction with hyaluronan, CD44 serves as an adhesion molecule in cell–substrate and cell–cell interactions, lymphocyte recruitment to inflammatory sites, and tumor metastasis [14] , [15] , [16] , [17] . The size of the CD44 molecule ranges from the standard 85–95 kD form (CD44s) to larger variant isoforms of 200 kD or more due to RNA splicing and post-translational modifications [18] . Functional characterization of different isoforms of the CD44 family, however, is still limited. Many cancer cell types express high levels of specific variants of CD44 [19] . The animal model studies have shown that interfering with the binding of CD44 to its ligand inhibits local tumor growth and metastatic spread [20] , [21] . During tumor metastasis, cells detach from the primary tumor, penetrate the basement membrane into the connective tissue, and invade adjacent organs structures, including blood vessels. Tumor cells are subsequently transported to metastatic sites through the blood stream. However, the mechanisms by which CD44 modulates the tumor cell transendothelial migration process are not fully understood. In the present study, we demonstrated that metastatic breast cancer cells strongly express a ∼170 kD CD44 variant 4 (CD44v4). The expression level and localization pattern of CD44v4 in breast cancer cells is closely correlated with tumor cell migratory capability across TNF-α pre-activated HUVEC monolayers. Our results further showed that CD44v4 is highly decorated with E-selectin binding sLe x moieties and serves as a major adhesive molecule in mediating breast cancer cell transendothelial metastasis. RESULTS HUVEC monolayers cultured on collagen-coated permeable Transwell filters were used as a model for endothelial cell monolayers to assess the transmigration of breast cancer cells. HUVEC monolayers were pre-activated with 25 ng/ml TNF-α for 6 h to upregulate the expression of adhesion molecules before the tumor migration assay. Five breast cancer cell lines including MDA-MB-231, MDA-MB-435, MDA-MB-468, T47D, and MCF-7 were assessed for their migratory capability across HUVEC monolayers. The general migratory capability of these five breast cancer cells has been well-studied [15] , [22] – [25] . Various breast cancer cells have a marked differential migratory capability. Among five cancer cell lines, MDA-MB-231, MDA-MB-435 and MDA-MB-468 have a higher invasive ability and are generally regarded as metastatic breast cancer cells while MCF-7 and T47D cells have a lower invasive ability and are regarded as non-metastatic cells. As shown in Figure 1A , MDA-MB-231 had the highest transmigration rate across TNF-α pre-activated HUVEC monolayers while MDA-MB-435 and MDA-MB-468 cells demonstrated relatively modest transmigration. Compared to these metastatic breast cancer cells, MCF-7 cells and T47D cells had a significantly lower transmigration rate. The transmigration of MDA-MB-231, MDA-MB-435 and MDA-MB-468 cross TNF-α pre-activated HUVEC monolayers was further characterized in the presence of various functional inhibitory antibodies. As shown in Fig. 1B , migration of MDA-MB-231 cells cross HUVEC monolayers was significantly blocked by anti-E-selectin antibody, but not by inhibitory antibodies against LFA-1 or VLA-4 ( Fig. 1B ), suggesting that metastasis of breast cancer cells across TNF-α pre-activated HUVEC monolayers is specifically dependent on HUVEC E-selectin. Similar inhibition by anti-E-selectin antibody on tumor cell transendothelial migration was observed in both MDA-MB-435 and MDA-MB-468 cell migration

Read the complete text